There is a particular kind of scientist who does not simply observe the world through existing lenses but insists on grinding entirely new glass. Joe Beechem is that kind of scientist. As Chief Scientific Officer and Senior Vice President of Bruker Spatial Biology, Beechem has spent more than three decades building instruments capable of doing things that were previously impossible at this scale and resolution: looking at a preserved slice of human tissue and revealing, with extraordinary precision, which of the roughly 22,000 protein-coding genes are being expressed, which proteins are present, and where within that tissue each molecular signal resides.
This is not an incremental improvement on what came before. It is a different way of seeing altogether. The world Dr. Beechem entered when he began his career was one in which molecular biology was largely practiced in solution. Tissues were ground up. Cells were dissolved. The architectural context of disease, the neighborhood in which a cancer cell resided, the proximity of an immune cell to a tumor boundary, the molecular conversation between one cell type and the next, was routinely destroyed in the very act of trying to study it. What Beechem and his colleagues have done, systematically and over decades, is to reverse that logic. They have built tools that treat the location of a molecule not as a detail to be discarded but as a primary biological fact, as important as the molecule’s identity itself.
A Career Built at the Intersection of Everything
The path to where Dr. Beechem stands today began with eleven years as a tenured faculty member at Vanderbilt University School of Medicine. It was there that he developed the scientific fluency, particularly in biophysics and quantitative biology, that would underpin everything that followed. Vanderbilt, it turned out, was a beginning and not a destination.
What followed was more than twenty-five years of technology development at a succession of companies that form a kind of genealogy of modern life science: Molecular Probes, Invitrogen, Life Technologies, and eventually NanoString Technologies, where he arrived in 2012 as Senior Vice President of Research and Development and Chief Scientific Officer. At each stage, Dr. Beechem brought with him a conviction that the most interesting problems were not the ones that had already been given tools, but the ones that had not yet been given the right questions.
The breadth of his scientific output across this period is, on reflection, extraordinary. His more than 400 peer-reviewed publications span fields that share almost nothing on the surface: spatial biology, cancer immunology, infectious disease, medicine, genomics, proteomics, biomathematics, physics, chemistry, and spectroscopy. His career citation count exceeds 17,000, and his h-index stands at 67, a figure that places him among the most consequential scientists working at the boundary of biology and technology. These are not decorative statistics. They are a measure of how many other scientists have found his work useful, have built upon it, and have carried it into domains he had not yet reached himself.
Three Platforms That Rewrote the Rulebook
The three platforms at the center of Dr. Beechem’s legacy represent, taken together, one of the most sustained and consequential technological achievements in the modern history of molecular biology.
The first is the GeoMx Digital Spatial Profiler, for which Dr. Beechem served as co-inventor and commercial technical lead developer. GeoMx enables whole-transcriptome profiling of RNA at up to 22,000-plex and proteins at up to 1,250-plex, using UV-light-directed next-generation sequencing readout of biobanked FFPE tissue sections. The landmark publication describing this work appeared in Nature Biotechnology, volume 38, in May 2020, with Merritt and colleagues as co-authors.
The number 22,000 deserves its own moment of attention. It corresponds, roughly, to the total count of protein-coding genes in the human genome. GeoMx can measure all of them simultaneously within a single preserved tissue section while preserving the positional context of where each molecular signal originates.
The second platform, CosMx Spatial Molecular Imager, pushes tissue-context mapping further still, down to the level of individual cells and the structures within them. CosMx achieves single-cell and subcellular measurement of RNA molecules at up to 19,000-plex and proteins at up to 76-plex. This work appeared in Nature Biotechnology, volume 40, in December 2022, with He and colleagues as co-authors. A single human cell spans, on average, between ten and twenty micrometers in diameter. CosMx can not only identify that cell but also map the subcellular addresses of its molecular messages.
The third platform, AtoMx Spatial Informatics Platform, is the computational architecture that makes the scale of the other two tenable. AtoMx is a cloud-based system capable of processing and analyzing up to 100 million spatially resolved single cells simultaneously. At present, it houses billions of spatially resolved cells and massive volumes of tissue-scale molecular data. These figures represent the construction of a new kind of scientific infrastructure, a living biological archive assembled cell by cell, molecule by molecule, coordinate by coordinate.
The Lab That Keeps Going Further
Dr. Beechem leads a multidisciplinary research team at NanoString, a Bruker company headquartered in Seattle, Washington. In its current form, that team devotes its collective effort to technology development for high-dimensional multiomic spatial biology applications. The phrase “unlimited-plex” is not a marketing flourish. It is a scientific position: the assertion that there is no fixed ceiling on the number of molecules that should be measured simultaneously within intact tissue, and that any current limitation is simply a technical problem waiting to be solved.
In November 2024, the team published a preprint on bioRxiv documenting the achievement of full subcellular imaging of the entire protein-coding transcriptome. The implications of that result will take years to fully unfold across the field. At its most immediate level, it means that researchers can now examine a single cell and account for every protein-coding RNA message within it while preserving positional precision.
A Scientist Whose Work Travels
One of the more telling dimensions of Dr. Beechem’s career is the range of audiences to whom he has carried this work. He has lectured at many of the world’s leading medical centers, major pharmaceutical organizations, biotechnology companies, and investment groups that support innovation in the life sciences. He is not a scientist who publishes and retreats. He is one who insists that the work be understood, used, and extended by others.
That impulse to share, to teach, to place new capabilities into the hands of people who will carry them in directions their creator could not have anticipated, runs through his career like a single unbroken thread. It is there in the publications, in the lectures, and in the platforms he built, not just for his own team but for the broader scientific community. It is, perhaps, the most distinctly human quality in a career defined by technical achievement: the belief that the point of seeing more clearly is not to see alone, but to show others what you have found.
Read More: Global Leaders Driving AI & High-Plex Tissue Analysis 2026
